| Literature DB >> 27407123 |
David S Ettinger1, Douglas E Wood1, Wallace Akerley1, Lyudmila A Bazhenova1, Hossein Borghaei1, David Ross Camidge1, Richard T Cheney1, Lucian R Chirieac1, Thomas A D'Amico1, Thomas Dilling1, Michael Dobelbower1, Ramaswamy Govindan1, Mark Hennon1, Leora Horn1, Thierry M Jahan1, Ritsuko Komaki1, Rudy P Lackner1, Michael Lanuti1, Rogerio Lilenbaum1, Jules Lin1, Billy W Loo1, Renato Martins1, Gregory A Otterson1, Jyoti D Patel1, Katherine M Pisters1, Karen Reckamp1, Gregory J Riely1, Steven E Schild1, Theresa A Shapiro1, Neelesh Sharma1, Scott J Swanson1, James Stevenson1, Kurt Tauer1, Stephen C Yang1, Kristina Gregory1, Miranda Hughes1.
Abstract
These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.Entities:
Mesh：
Year: 2016 PMID： 27407123 DOI： 10.6004/jnccn.2016.0087
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908